Last updated July 6, 2026
Key finding
HbA1c decreased significantly from 10.4 ± 2.4 to 7.2 ± 1.7 (p < 0.001)
This study evaluated the effects of chromium supplementation on glycemic control in patients with type 2 diabetes, finding significant improvements in HbA1c and fasting plasma glucose levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of chromium supplementation on glycemic control in patients with type 2 diabetes, finding significant improvements in HbA1c and fasting plasma glucose levels.
These findings suggest that chromium supplementation could be a beneficial adjunct therapy for managing blood sugar levels and improving cholesterol profiles in patients with type 2 diabetes. This could lead to better overall health outcomes and reduced risk of diabetes-related complications.
The study did not assess long-term effects of chromium supplementation. Sample size and demographic diversity were not specified. No placebo control group was mentioned.
Published in
Publication details and source links for this paper.
Fatima A. The Impact of Chromium Supplementation on Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Journal of Medicine and Life. 2023;16(8):1178-1182. doi:10.25122/jml-2023-0081
HbA1c decreased significantly from 10.4 ± 2.4 to 7.2 ± 1.7 (p < 0.001).
Fasting plasma glucose decreased significantly (p < 0.001).
Total cholesterol decreased significantly (p = 0.002).
HDL levels increased significantly (p = 0.006).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Chromium supplementation and Fasting Plasma Glucose (FPG), HDL cholesterol, HbA1c, and 2 more.
This study contributes evidence to
Primary intervention
Chromium supplementation
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
5
Evidence pairs
1489
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Chromium supplementation → Fasting Plasma Glucose (FPG)
Chromium supplementation → Fasting Plasma Glucose (FPG)
Chromium supplementation → Total cholesterol
Chromium supplementation → Total cholesterol
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Chromium supplementation and Fasting Glucose, Chromium supplementation and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Supplements
Supplements
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies on Chromium supplementation
Contributes to Chromium supplementation evidence base.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Chromium supplementation appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Chromium supplementation appears to improve hdl cholesterol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Chromium supplementation appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Chromium supplementation appears to improve total cholesterol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Total cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
